News & Updates

Back to All

Kedalion Therapeutics Adds Dana G. Mead, Jr. to Board of Directors

Menlo Park, CA, April 17, 2017 – Kedalion Therapeutics, Inc., an early-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced the addition of Dana G. Mead, Jr. to its board of directors as an independent director.

“I am delighted to welcome Dana to Kedalion and look forward to adding his invaluable background and experience to our board of directors,” said Mark Blumenkranz, M.D., M.M.S., Executive Chairman, Kedalion. “Dana brings significant background and experience in both the operational side of the business as well as the investor side of the business, both of which will be areas of great importance to the company as we guide its growth.”

Mr. Mead is President and Chief Executive Officer of Beaver-Visitec International. Prior to that, he was a strategic advisor and partner in the life sciences practice of Kleiner Perkins Caulfield & Byers (KPCB), a leading venture capital firm, where he helped identify and grow early-stage healthcare companies. Previously, he held a series of senior-level positions at Guidant Corporation and served in various sales and marketing roles in the ophthalmic groups at Allergan and Johnson & Johnson earlier in his career. Mr. Mead has a Bachelor’s Degree from Lafayette College and an M.B.A. degree from the University of Southern California.


About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit


Download a PDF version of this press release >